Harnessing the Potential of Lipid Nanoparticles for the Delivery of Chemically Modified SiRNA to Combat Hepatic Adenovirus Infection
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Amplifying antitumor immunity with iPSC-derived exosomes.
Shubhra Q, Veranic P, Wang Z Mol Ther. 2023; 31(8):2300-2301.
PMID: 37467746 PMC: 10422008. DOI: 10.1016/j.ymthe.2023.07.001.
References
1.
Hu B, Huang Y
. siRNA targeting ANGPTL3 stands in the spotlight for lipid-lowering therapy. Mol Ther Nucleic Acids. 2023; 32:369-370.
PMC: 10148020.
DOI: 10.1016/j.omtn.2023.03.020.
View
2.
Foster D, Brown C, Shaikh S, Trapp C, Schlegel M, Qian K
. Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates. Mol Ther. 2018; 26(3):708-717.
PMC: 5910670.
DOI: 10.1016/j.ymthe.2017.12.021.
View
3.
Siegrist E, Sassine J
. Antivirals With Activity Against Mpox: A Clinically Oriented Review. Clin Infect Dis. 2022; 76(1):155-164.
PMC: 9825831.
DOI: 10.1093/cid/ciac622.
View
4.
Feczko T, Fodor-Kardos A, Sivakumaran M, Haque Shubhra Q
. In vitro IFN-α release from IFN-α- and pegylated IFN-α-loaded poly(lactic-co-glycolic acid) and pegylated poly(lactic-co-glycolic acid) nanoparticles. Nanomedicine (Lond). 2016; 11(16):2029-34.
DOI: 10.2217/nnm-2016-0058.
View
5.
Bao L, Hu J, Zhan B, Chi M, Li Z, Wang S
. Structural insights into RNase J that plays an essential role in Mycobacterium tuberculosis RNA metabolism. Nat Commun. 2023; 14(1):2280.
PMC: 10119312.
DOI: 10.1038/s41467-023-38045-z.
View